Integra LifeSciences Holdings Corporation
IART
$13.09
$0.030.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.99% | 3.53% | 6.19% | 4.47% | 1.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.99% | 3.53% | 6.19% | 4.47% | 1.45% |
| Cost of Revenue | 10.35% | 10.60% | 12.27% | 10.50% | 8.72% |
| Gross Profit | 1.30% | -1.19% | 2.26% | 0.70% | -3.00% |
| SG&A Expenses | 5.25% | 7.78% | 11.89% | 11.68% | 6.03% |
| Depreciation & Amortization | 10.02% | 14.94% | 20.92% | 14.94% | 5.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.17% | 9.11% | 12.18% | 11.14% | 7.02% |
| Operating Income | -10.93% | -30.48% | -27.38% | -29.68% | -26.44% |
| Income Before Tax | -4,474.80% | -2,165.68% | -193.45% | -122.49% | -110.24% |
| Income Tax Expenses | -829.04% | -1,809.25% | -341.75% | -184.73% | -134.53% |
| Earnings from Continuing Operations | -7,469.30% | -2,216.99% | -171.97% | -110.25% | -106.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7,469.30% | -2,216.99% | -171.97% | -110.25% | -106.49% |
| EBIT | -10.93% | -30.48% | -27.38% | -29.68% | -26.44% |
| EBITDA | 3.24% | -9.81% | -10.95% | -15.28% | -16.56% |
| EPS Basic | -7,247.67% | -2,300.24% | -174.05% | -110.39% | -107.17% |
| Normalized Basic EPS | -28.29% | -46.35% | -39.21% | -38.41% | -31.23% |
| EPS Diluted | -7,030.35% | -2,356.29% | -175.70% | -110.77% | -107.49% |
| Normalized Diluted EPS | -28.29% | -46.33% | -39.15% | -38.27% | -31.08% |
| Average Basic Shares Outstanding | -1.04% | -2.16% | -3.04% | -3.89% | -5.07% |
| Average Diluted Shares Outstanding | -1.04% | -2.20% | -3.13% | -4.12% | -5.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |